Evaluation of the Safety and Efficacy of Topical Besifloxacin Ophthalmic Suspension, 0.6% Compared With Gatifloxacin, 0.3% Ophthalmic Solution for the Treatment of Presumed Bacterial Conjunctivitis in Subjects From Birth to 31 Days of Age

Trial Profile

Evaluation of the Safety and Efficacy of Topical Besifloxacin Ophthalmic Suspension, 0.6% Compared With Gatifloxacin, 0.3% Ophthalmic Solution for the Treatment of Presumed Bacterial Conjunctivitis in Subjects From Birth to 31 Days of Age

Discontinued
Phase of Trial: Phase III

Latest Information Update: 01 Nov 2014

At a glance

  • Drugs Besifloxacin (Primary) ; Gatifloxacin
  • Indications Bacterial infections; Conjunctivitis
  • Focus Therapeutic Use
  • Sponsors Bausch & Lomb
  • Most Recent Events

    • 05 Apr 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 25 Jan 2013 Planned End Date changed from 1 Jul 2013 to 1 Jul 2014 as reported by ClinicalTrials.gov.
    • 08 Apr 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top